| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | R1626 | |
| 3 | Mechanism | Nucleoside Polymerase Inhibitor | |
| 4 | Indication | Hepatitis C | |
| 5 | Safety | Neutropenia | |
| 6 | Clinical Trials | ||
| 7 | Phase IIb "POLI" study - n=500 | ||
| 8 | |||
| 9 | |||
| 10 | Phase IIa "4+44" 4 weeks of triple followed by 44 weeks of Standard of Care (Pegasys+Copegus) - EASL 2008 | ||
| 11 | 84% were UND in g1 patients versus 65% for control group at the end of treatment. | ||
| 12 | |||
| 13 | 3.9 log mean maximum reduction shown in 200mg q8h. |